Mitobridge, Inc., is a leader in the emerging field of mitochondria-related drug discovery and development. The company is utilizing its innovative screening platform to identify and develop novel therapeutics that improve mitochondria function and provide treatments for mitochondrial genetic diseases, musculoskeletal and neurodegenerative disorders, as well as diseases and conditions of aging. Mitobridge’s scientific founders and advisors include world-renowned leaders in biology and mitochondrial function. In November 2017, Mitobridge and Astellas Pharmaceuticals Inc. announced that Astellas had exercised its exclusive option to purchase Mitobridge for $225 million plus future contingent payments of up to $225 million based on the advances in clinical programs.